Tiziana Palumbo1, Kojiro Nakamura, Charles Lassman, Yoko Kidani, Steven J Bensinger, Ronald Busuttil, Jerzy Kupiec-Weglinski, Ali Zarrinpar. 1. 1 Division of Liver and Pancreas Transplantation, Department of Surgery, Dumont-UCLA Transplant Center, David Geffen School of Medicine at University of California, Los Angeles, CA. 2 Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA. 3 Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles, CA. 4 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, CA.
Abstract
BACKGROUND: Bruton tyrosine kinase (Btk) is a central player in multiple signaling pathways of lymphoid and myeloid cells. Myeloid cells are crucial early effectors in organ ischemia-reperfusion (IR) injury. BTKB66 is a selective, irreversible inhibitor of Btk. In this study, we hypothesized that Btk inhibition would reduce hepatocellular injury in a murine model of liver warm hepatic IR. METHODS: First, BTKB66 was tested in in vitro models of lipopolysaccharide-mediated neutrophil and macrophage activation. Then, to assess its efficacy in vivo, BTKB66 was administered orally to mice for 7 days before subjecting them to 90 minutes of warm hepatic ischemia followed by reperfusion for 6 or 24 hours. Clinical and pathologic features in the livers, including AST, ALT, and a panel of cytokines and chemokines, were examined. RESULTS: BTKB66 potently inhibited lipopolysaccharide-mediated activation of bone marrow-derived neutrophils and macrophages in vitro. It also reduced the severity of IR injury as determined by AST and ALT levels, as well as immune cell infiltrates. BTKB66 significantly decreased hepatic markers of sterile inflammation, such as C-X-C motif chemokine 1, C-X-C motif chemokine 2, and C-X-C motif chemokine 10, in parallel with depression of serum markers of the myeloid cell activation, such as CCL5, CCL11, and C-X-C motif chemokine 5. CONCLUSIONS: BTKB66 treatment ameliorated hepatocellular injury in a well-established model of liver partial warm ischemia and in situ reperfusion. These findings confirm that neutrophil recruitment and activation play an essential role in IR stress, and that targeting Btk activity may provide a useful approach for preventing hepatocellular damage and improving outcomes in liver transplantation.
BACKGROUND:Bruton tyrosine kinase (Btk) is a central player in multiple signaling pathways of lymphoid and myeloid cells. Myeloid cells are crucial early effectors in organ ischemia-reperfusion (IR) injury. BTKB66 is a selective, irreversible inhibitor of Btk. In this study, we hypothesized that Btk inhibition would reduce hepatocellular injury in a murine model of liver warm hepatic IR. METHODS: First, BTKB66 was tested in in vitro models of lipopolysaccharide-mediated neutrophil and macrophage activation. Then, to assess its efficacy in vivo, BTKB66 was administered orally to mice for 7 days before subjecting them to 90 minutes of warm hepatic ischemia followed by reperfusion for 6 or 24 hours. Clinical and pathologic features in the livers, including AST, ALT, and a panel of cytokines and chemokines, were examined. RESULTS: BTKB66 potently inhibited lipopolysaccharide-mediated activation of bone marrow-derived neutrophils and macrophages in vitro. It also reduced the severity of IR injury as determined by AST and ALT levels, as well as immune cell infiltrates. BTKB66 significantly decreased hepatic markers of sterile inflammation, such as C-X-C motif chemokine 1, C-X-C motif chemokine 2, and C-X-C motif chemokine 10, in parallel with depression of serum markers of the myeloid cell activation, such as CCL5, CCL11, and C-X-C motif chemokine 5. CONCLUSIONS: BTKB66 treatment ameliorated hepatocellular injury in a well-established model of liver partial warm ischemia and in situ reperfusion. These findings confirm that neutrophil recruitment and activation play an essential role in IR stress, and that targeting Btk activity may provide a useful approach for preventing hepatocellular damage and improving outcomes in liver transplantation.
Authors: Maria Cecilia S Freitas; Yoichiro Uchida; Danyun Zhao; Bibo Ke; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Liver Transpl Date: 2010-05 Impact factor: 5.799
Authors: Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy Journal: Proc Natl Acad Sci U S A Date: 2010-07-06 Impact factor: 11.205
Authors: A M Soler-Rodriguez; H Zhang; H S Lichenstein; N Qureshi; D W Niesel; S E Crowe; J W Peterson; G R Klimpel Journal: J Immunol Date: 2000-03-01 Impact factor: 5.422
Authors: C I Smith; B Baskin; P Humire-Greiff; J N Zhou; P G Olsson; H S Maniar; P Kjellén; J D Lambris; B Christensson; L Hammarström Journal: J Immunol Date: 1994-01-15 Impact factor: 5.422
Authors: S Tsukada; D C Saffran; D J Rawlings; O Parolini; R C Allen; I Klisak; R S Sparkes; H Kubagawa; T Mohandas; S Quan Journal: Cell Date: 1993-01-29 Impact factor: 41.582
Authors: T S Dulkanchainun; J A Goss; D K Imagawa; G D Shaw; D M Anselmo; F Kaldas; T Wang; D Zhao; A A Busuttil; H Kato; N G Murray; J W Kupiec-Weglinski; R W Busuttil Journal: Ann Surg Date: 1998-06 Impact factor: 12.969
Authors: Shoichi Kageyama; Hirofumi Hirao; Kojiro Nakamura; Bibo Ke; Min Zhang; Takahiro Ito; Antony Aziz; Damla Oncel; Fady M Kaldas; Ronald W Busuttil; Rebecca A Sosa; Elaine F Reed; Jesus A Araujo; Jerzy W Kupiec-Weglinski Journal: Am J Transplant Date: 2018-08-24 Impact factor: 8.086
Authors: Jan M Herter; Andreas Margraf; Stephanie Volmering; Benedito Eduardo Correia; J Michael Bradshaw; Angelina Bisconte; Ronald J Hill; Claire L Langrish; Clifford A Lowell; Alexander Zarbock Journal: Br J Pharmacol Date: 2017-12-22 Impact factor: 8.739
Authors: Yuan Liu; Tianfei Lu; Cheng Zhang; Zhengze Xue; Jin Xu; Ronald W Busuttil; Qiang Xia; Ning Xu; Jerzy W Kupiec-Weglinski; Haofeng Ji Journal: Transplantation Date: 2019-08 Impact factor: 4.939
Authors: Caroline E O'Riordan; Gareth S D Purvis; Debora Collotta; Nadine Krieg; Bianka Wissuwa; Madeeha H Sheikh; Gustavo Ferreira Alves; Shireen Mohammad; Lauren A Callender; Sina M Coldewey; Massimo Collino; David R Greaves; Christoph Thiemermann Journal: Front Immunol Date: 2020-10-07 Impact factor: 7.561
Authors: Ivan Linares; Kaveh Farrokhi; Juan Echeverri; Johan Moritz Kaths; Dagmar Kollmann; Matyas Hamar; Peter Urbanellis; Sujani Ganesh; Oyedele A Adeyi; Paul Yip; Markus Selzner; Nazia Selzner Journal: PLoS One Date: 2018-04-04 Impact factor: 3.240
Authors: Raquel Benedé-Ubieto; Olga Estévez-Vázquez; Feifei Guo; Chaobo Chen; Youvika Singh; Helder I Nakaya; Manuel Gómez Del Moral; Arantza Lamas-Paz; Laura Morán; Nuria López-Alcántara; Johanna Reissing; Tony Bruns; Matías A Avila; Eva Santamaría; Marina S Mazariegos; Marius Maximilian Woitok; Ute Haas; Kang Zheng; Ignacio Juárez; José Manuel Martín-Villa; Iris Asensio; Javier Vaquero; Maria Isabel Peligros; Josepmaria Argemi; Ramón Bataller; Javier Ampuero; Manuel Romero Gómez; Christian Trautwein; Christian Liedtke; Rafael Bañares; Francisco Javier Cubero; Yulia A Nevzorova Journal: Hepatol Commun Date: 2021-03-11